Haemonetics Management
Management criteria checks 3/4
Haemonetics' CEO is Chris Simon, appointed in May 2016, has a tenure of 10.33 years. total yearly compensation is $12.04M, comprised of 9.1% salary and 90.9% bonuses, including company stock and options. directly owns 0.76% of the company’s shares, worth $36.87M. The average tenure of the management team and the board of directors is 4.4 years and 8.7 years respectively.
Key information
Chris Simon
Chief executive officer
US$12.0m
Total compensation
| CEO salary percentage | 9.13% |
| CEO tenure | 10.3yrs |
| CEO ownership | 0.8% |
| Management average tenure | 4.4yrs |
| Board average tenure | 8.7yrs |
Recent management updates
Recent updates
Narrative Update • Sep 10
HAE: CSL Plasma Renewal And Vascular Closure Progress Will Shape FY27 Rerating Potential
Haemonetics' analyst fair value estimate has moved from $96.90 to $108.40 as analysts factor in higher Street price targets tied to the renewed CSL plasma supply agreement, NexSys PCS adoption, and the potential for what some describe as meaningful adjusted EPS upside if lost plasma business is gradually recaptured. Analyst Commentary Recent research commentary around Haemonetics has centered on the renewed CSL plasma relationship, the NexSys PCS platform and what these could mean for valuation, earnings power and execution over the next few years.
Narrative Update • Aug 27
HAE: Recent Plasma Deal And High Expectations Will Drive Catalyst Fatigue Risk
Haemonetics' updated fair value estimate increases from $65.93 to $86.00 as analysts raise price targets into the $100 to $120 range, citing stronger support from plasma supply agreements, productivity benefits from NexSys PCS with Persona PLUS, and improved expectations for profitability and valuation multiples. Analyst Commentary Recent Street research on Haemonetics shows a cluster of higher price targets, generally in a US$90 to US$120 range, with most firms maintaining positive ratings.Seeking Alpha • Aug 21
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model
Summary Haemonetics is a medtech company that’s increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential. Lastly, I think HAE’s valuation still looks reasonable despite the impressive rally during 2026. So, while I reckon there’s less margin of safety today, HAE still looks compelling as a speculative “Buy” for long-term investors. Read the full article on Seeking AlphaNarrative Update • Aug 12
HAE: FY27 Execution And Vascular Closure Advances Will Shape Rerating Potential
Haemonetics' analyst fair value estimate has increased by $10 to $96.90 as analysts respond to a series of higher price targets tied to Q1 beat and raise results, expectations for stronger FY27 performance, and ongoing optimism around profitability and debt reduction. Analyst Commentary Recent research on Haemonetics points to a broadly constructive view on the stock, with several bullish analysts lifting price targets following Q1 results and updated outlooks.Narrative Update • Jul 29
HAE: Recent Index Additions And Buybacks Will Face Catalyst Fatigue Risk
Haemonetics' analyst fair value estimate has moved from $62.00 to about $65.93 as analysts factor in recent price target increases tied to perceived Plasma and Hospital upside, sector model updates, and changing expectations around near-term catalysts. Analyst Commentary Recent research on Haemonetics shows a mix of optimism around Plasma and Hospital opportunities and caution around how much good news is already reflected in the stock.Narrative Update • Jun 24
HAE: Vascular Closure Optimism Will Face Ongoing Execution And Reporting Restructure Risk
Haemonetics enters this narrative update with a higher Street price target range, highlighted by Citi lifting its target to $70 from $64 and BofA raising its target to $80 from $72. Analysts reference updated medical technology models, a view that vascular closure may have turned a corner, and what they see as conservative guidance with potential upside across all three segments.Narrative Update • Jun 08
HAE: Vascular Closure Optimism Will Face Growing Concerns Over Execution Risk
Haemonetics' analyst price targets have shifted higher, with recent moves from $64 to $70 and from $72 to $80, as analysts point to solid sector fundamentals, a perceived turning point in vascular closure, and what they view as more durable plasma upside. Analyst Commentary Recent Street research on Haemonetics shows a mix of supportive and cautious views.Analysis Article • May 27
Haemonetics' (NYSE:HAE) Conservative Accounting Might Explain Soft Earnings
The market for Haemonetics Corporation's ( NYSE:HAE ) shares didn't move much after it posted weak earnings recently...Narrative Update • May 25
HAE: Vascular Closure And Plasma Upside Will Offset Recent Cautious Repricing
Haemonetics' updated analyst price target has shifted from $64.00 to $62.00 as analysts balance slightly adjusted fair value and profitability assumptions with views that potential upside to guidance in vascular closure and plasma could prove more durable over time. Analyst Commentary Recent Street research on Haemonetics reflects a mix of optimism around vascular closure and plasma, alongside a series of lower price targets that highlight ongoing execution and growth questions.Narrative Update • May 09
HAE: New Approvals And Trials Will Support Upside Despite Cautious Repricing
Haemonetics' updated analyst price target reflects a modest reset in expectations, with several firms trimming their targets by $4 to $12 as analysts factor in slightly lower revenue growth assumptions, a marginally higher profit margin outlook, and a small adjustment to the assumed future P/E multiple. Analyst Commentary Recent research shows a cluster of bearish adjustments to Haemonetics' price targets, with several bearish analysts trimming their numbers in close succession.Narrative Update • Apr 22
HAE: Pipeline And Product Updates Will Offset Cautious Sector Repricing
Haemonetics' implied fair value price target has been revised to $64 from $70 as analysts factor in updated sector peer multiples, adjustments to revenue growth and margin assumptions, and a slightly higher discount rate following recent Street research updates. Analyst Commentary Recent Street research around Haemonetics reflects a more cautious tone as several bearish analysts trim their price targets and revisit their assumptions on growth, margins, and valuation risk.Narrative Update • Apr 08
HAE: Vivasure Acquisition Will Support Earnings Quality Despite Sector Repricing
Haemonetics' updated fair value estimate has edged down by about $1, reflecting analysts' recent trims to price targets across the medical technology group, even as they point to healthy sector fundamentals and mixed revisions following the Vivasure acquisition. Analyst Commentary Recent research views on Haemonetics highlight a split between analysts who see upside from the Vivasure acquisition and those who are resetting expectations across the medical technology group after recent sector volatility.Narrative Update • Mar 25
HAE: Vivasure Deal And Pipeline Progress Will Support Future Share Recovery
Analysts have reduced the Haemonetics fair value estimate to $70 from $74. Recent target resets in the group, including Citi's move to $70, reflect updated assumptions around growth, margins and the P/E multiple for the stock.Narrative Update • Mar 10
HAE: Vivasure Deal And 2026 Outlook Will Support Earnings Quality
Analysts have modestly adjusted their views on Haemonetics, with several firms trimming price targets by $10 to $18 and one small $1 upward revision. These changes reflect updated assumptions on valuation multiples, while fair value and key model inputs remain broadly unchanged.Narrative Update • Feb 23
HAE: Vivasure Acquisition And FY26 Outlook Will Support Margin Recovery
The analyst price target for Haemonetics has been reduced by $3.70, with analysts pointing to a slightly higher discount rate, a lower fair value estimate and some pressure on projected profit margins, even as they continue to apply a higher forward P/E and updated revenue growth assumptions in their models. Analyst Commentary Recent Street research on Haemonetics has been mixed, with several firms trimming their price targets while at least one firm has lifted its target in connection with the Vivasure Medical acquisition.Narrative Update • Feb 08
HAE: Vivasure Acquisition Will Drive Execution And Support Future Share Recovery
Analysts have trimmed their fair value estimate for Haemonetics to about $74.00, reflecting mixed Street price target moves that weigh recent target cuts from several firms against at least one increase tied to a favorable view of the Vivasure Medical acquisition. Analyst Commentary Recent Street research around Haemonetics reflects a split view, with several bearish analysts trimming price targets and a smaller group seeing upside tied to the Vivasure Medical acquisition.Narrative Update • Jan 25
HAE: Vivasure Deal And Buyback Will Shape Execution And Share Recovery
Analysts have lifted their price target for Haemonetics from about $58 to roughly $74.82, citing recent Street research that points to higher assumed revenue growth, slightly stronger profit margins, a higher future P/E, and supportive views on the Vivasure acquisition and recent earnings execution. Analyst Commentary Recent Street research has centered on two main themes for Haemonetics, the Vivasure acquisition and the company’s latest earnings print.Narrative Update • Jan 11
HAE: Achievable Hospital Reset And FY26 Outlook Will Support Gradual Recovery
Narrative Update on Haemonetics Analysts have inched up their price target for Haemonetics, with updated fair value rising from about US$90 to roughly US$92, citing recent price target increases, company performance that met or exceeded expectations across segments, and what they view as more achievable guidance and improved credibility on execution and messaging. Analyst Commentary Recent commentary has focused on how Haemonetics is executing against expectations, how realistic its guidance looks, and what that might mean for valuation support and potential growth in the medium term.Analysis Article • Jan 06
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Dec 24
HAE: Achievable Hospital Guidance Reset Will Support Gradual Share Recovery
Analysts have modestly raised their price target on Haemonetics to approximately $90 from about $86, citing stronger than expected execution across all segments, a more achievable Hospital guidance reset, and an improved long term sales outlook that supports higher growth and valuation assumptions. Analyst Commentary Analysts see the recent quarter as a constructive inflection point for Haemonetics, with improved guidance and execution supporting a modestly higher valuation framework, though some caution remains around sustainability of growth and delivery against new targets.Narrative Update • Dec 10
HAE: Broad Outperformance And Achievable Hospital Guidance Will Support Gradual Share Recovery
Analysts have modestly raised their price target on Haemonetics to approximately $86 from about $85, citing broad-based outperformance, more achievable Hospital guidance, and an upgraded FY26 sales outlook that supports a gradual recovery in the shares. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the price target increase toward the high $80s reflects growing confidence in the company’s ability to sustain outperformance across all operating segments.Narrative Update • Nov 26
HAE: Solid Execution And Achievable Guidance Will Support Measured Share Recovery
Analysts have raised their price target for Haemonetics from $83 to approximately $84.55. They cite solid execution, an improved sales outlook, and increased confidence in the company's guidance and operational credibility.Narrative Update • Nov 12
HAE: Upbeat Execution And Reset Guidance Should Drive Share Price Recovery
Haemonetics' analyst price target has been raised from $76.27 to $83.00, as analysts cite improved execution, strong segment performance, and a more optimistic sales outlook as key drivers for the upward revision. Analyst Commentary Following recent quarterly results and the revised price target, analysts have shared both optimistic highlights and points of caution regarding Haemonetics' outlook and valuation.Analysis Article • Nov 07
A Piece Of The Puzzle Missing From Haemonetics Corporation's (NYSE:HAE) 36% Share Price Climb
Haemonetics Corporation ( NYSE:HAE ) shares have had a really impressive month, gaining 36% after a shaky period...Narrative Update • Oct 28
Execution Challenges Will Shift Outlook For Global Plasma And Hemostasis Expansion
Haemonetics’ analyst price target has been revised lower by analysts to approximately $76 from $77. This change reflects concerns about execution within the Interventional Technologies segment, despite confidence in the company’s long-term value.Narrative Update • Oct 14
Aging Demographics Will Expand Global Plasma And Hemostasis Markets
The analyst price target for Haemonetics has been lowered by approximately $1.73 to $76.91. Analysts cite ongoing concerns around sales execution and challenges in the Interventional Technologies segment.Narrative Update • Aug 08
Aging Demographics Will Expand Global Plasma And Hemostasis Markets
The decrease in Haemonetics' price target primarily reflects a significant reduction in consensus revenue growth forecasts, partially offset by improved net profit margin expectations, leading to a revised fair value of $85.18. What's in the News Haemonetics Corporation (NYSE:HAE) added to Russell 2000 Dynamic Index Valuation Changes Summary of Valuation Changes for Haemonetics The Consensus Analyst Price Target has fallen from $92.45 to $85.18.Seeking Alpha • Feb 20
Haemonetics: Almost Blood In The Streets
Summary Haemonetics shares have been trading at more appealing levels after a reduction in full-year sales guidance, trading at historically reasonable levels. The company, generating $1.3 billion in annual sales, has seen modest growth, with significant contributions from its plasma and hospital segments. Despite a cautious outlook due to suboptimal positioning in some units, Haemonetics aims for continued growth in 2025, aided by M&A efforts. Shares have fallen to $64, valuing the business at 3 times sales, with adjusted earnings multiples dropping to mid-teens multiple. The appeal is improving here. Read the full article on Seeking Alpha
New Narrative • Sep 03
Innovative Express Plus Technology And Strategic Market Expansion Set To Propel Revenue Growth
Innovation and R&D in Blood Management Technologies, including new products, are expected to increase market share and net margins through product differentiation.Seeking Alpha • Jun 21
Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Summary Haemonetics faces near-term revenue growth challenges due to the loss of its plasma collections business with CSL over the next two years. Management has used M&A to boost its revenue growth, including the very successful deal for Cardiva to enter vascular closure, but recent M&A deals have been more questionable. Haemonetics should see revenue reacceleration in FY'26, with long-term revenue growth of 6% to 7% and margin improvement driving a fair value above $100. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 27 2026 | n/a | n/a | US$96m |
| Mar 28 2026 | US$12m | US$1m | US$97m |
| Dec 27 2025 | n/a | n/a | US$175m |
| Sep 27 2025 | n/a | n/a | US$168m |
| Jun 28 2025 | n/a | n/a | US$163m |
| Mar 29 2025 | US$11m | US$1m | US$168m |
| Dec 28 2024 | n/a | n/a | US$130m |
| Sep 28 2024 | n/a | n/a | US$124m |
| Jun 29 2024 | n/a | n/a | US$115m |
| Mar 30 2024 | US$12m | US$1m | US$118m |
| Dec 30 2023 | n/a | n/a | US$127m |
| Sep 30 2023 | n/a | n/a | US$128m |
| Jul 01 2023 | n/a | n/a | US$137m |
| Apr 01 2023 | US$11m | US$1m | US$115m |
| Dec 31 2022 | n/a | n/a | US$96m |
| Oct 01 2022 | n/a | n/a | US$86m |
| Jul 02 2022 | n/a | n/a | US$68m |
| Apr 02 2022 | US$9m | US$945k | US$43m |
| Jan 01 2022 | n/a | n/a | US$23m |
| Oct 02 2021 | n/a | n/a | US$31m |
| Jul 03 2021 | n/a | n/a | US$64m |
| Apr 03 2021 | US$9m | US$963k | US$79m |
| Dec 26 2020 | n/a | n/a | US$108m |
| Sep 26 2020 | n/a | n/a | US$106m |
| Jun 27 2020 | n/a | n/a | US$96m |
| Mar 28 2020 | US$9m | US$937k | US$77m |
Compensation vs Market: Chris's total compensation ($USD12.04M) is above average for companies of similar size in the US market ($USD8.42M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Simon (62 yo)
10.3yrs
Tenure
US$12,044,701
Compensation
Mr. Christopher A. Simon, also known as Chris, has been the Chief Executive Officer and President of Haemonetics Corporation since May 16, 2016 and has been its Director since May 2016. He joined Haemoneti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 10.3yrs | US$12.04m | 0.76% $ 36.9m | |
| CFO, Executive VP & Financial Officer | 4.4yrs | US$3.62m | 0.042% $ 2.0m | |
| Executive VP & COO | 1.4yrs | US$3.34m | 0.0035% $ 170.6k | |
| Executive VP | 9.5yrs | US$3.41m | 0.076% $ 3.7m | |
| Executive VP & Chief Commercial Officer | 3.9yrs | US$3.04m | 0.015% $ 743.6k | |
| VP, Chief Accounting Officer & Principal Accounting Officer | 3.9yrs | no data | 0.0033% $ 161.4k | |
| VP of IR & Treasury | 6.9yrs | no data | no data | |
| Senior Director of Global Communications | no data | no data | no data | |
| Senior Vice President of Strategy & Corporate Development | 3.4yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 5.1yrs | no data | 0.050% $ 2.4m | |
| Senior VP & Chief Medical Officer | 3.4yrs | no data | no data | |
| President of Plasma Business Unit | 9yrs | no data | no data |
4.4yrs
Average Tenure
55.5yo
Average Age
Experienced Management: HAE's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 10yrs | US$12.04m | 0.76% $ 36.9m | |
| Independent Director | 8.9yrs | US$304.98k | 0.055% $ 2.7m | |
| Independent Director | 6.4yrs | US$292.98k | 0.034% $ 1.6m | |
| Independent Chairman | 8.7yrs | US$449.98k | 0.043% $ 2.1m | |
| Independent Director | 7.4yrs | US$299.98k | 0.037% $ 1.8m | |
| Independent Director | 20.7yrs | US$289.98k | 0.054% $ 2.6m | |
| Independent Director | 5.1yrs | US$306.73k | 0.028% $ 1.4m | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data |
8.7yrs
Average Tenure
72yo
Average Age
Experienced Board: HAE's board of directors are considered experienced (8.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/16 23:02 |
| End of Day Share Price | 2026/09/16 00:00 |
| Earnings | 2026/06/27 |
| Annual Earnings | 2026/03/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Haemonetics Corporation is covered by 24 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Michael Petusky | Barrington Research Associates, Inc. |
| Travis Steed | BofA Global Research |